Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hereditary Cancer in Clinical Practice
Published in: Hereditary Cancer in Clinical Practice 1/2016

Open Access 01-12-2016 | Reviewer acknowledgement

Thank you to all our manuscript reviewers in 2015

Authors: Jan Lubinski, Rodney J. Scott, Rolf Sijmons, Sarah M. Theissen

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2016

Login to get access

Contributing reviewers

The editors of Hereditary Cancer in Clinical Practice would like to thank all our reviewers who have contributed to the journal in 2015.
Without the participation of skilful reviewers, no academic journal could succeed, and we are grateful to the committed individuals who have given their time and expertise to the peer review of manuscripts for Hereditary Cancer in Clinical Practice. We look forward to your continued support in 2016.
Metadata
Title
Thank you to all our manuscript reviewers in 2015
Authors
Jan Lubinski
Rodney J. Scott
Rolf Sijmons
Sarah M. Theissen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2016
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-016-0047-4

Other articles of this Issue 1/2016

Hereditary Cancer in Clinical Practice 1/2016 Go to the issue

Review

Cytotoxic and targeted therapy for hereditary cancers

Research

Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study

Research

Differences in neuropsychological and behavioral parameters and brain structure in patients with familial adenomatous polyposis: a sibling-paired study

Research

Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer

Research

Pedigree based DNA sequencing pipeline for germline genomes of cancer families

Research

Association of polymorphisms with a family history of cancer and the presence of germline mutations in the BRCA1/BRCA2 genes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits